Oscotec Inc. As a leading discovery engine, their mission is to improve patients' lives by creating transformative therapies. Oscotec focuses on discovering small molecules with unique mechanisms of action and validating the drug-target-disease hypothesis through rigorous scientific research to achieve clinical proof-of-concept.

Their clinical pipeline consists of targeted therapeutics for immunology and oncology, including their flagship program SKI-O-703, a SYK inhibitor, currently undergoing Phase 2 clinical trials for rheumatoid arthritis (RA) and idiopathic thrombocytopenic purpura (ITP). Oscotec is also known as the proud inventor of lazertinib, a third-generation EGFR inhibitor developed by Janssen Pharma and Yuhan Corp. Furthermore, Oscotec is actively working on SKI-G-801, a selective FLT3/AXL inhibitor for acute myeloid leukemia (AML) and solid tumors.

Their discovery research focuses on first-in-class targets involved in cancer-related immune resistance, therapy resistance, and metastasis, aiming to provide ground-breaking solutions to potentially 'cure' cancers. Headquartered in Republic of Korea, Oscotec Inc. A, Korea Bio-Park, 700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488.

For further inquiries, please contact their Customer Center